PCSK9 Inhibitors Market Size
Market Size in USD Bn
CAGR16.2%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 16.2% |
| Market Concentration | High |
| Major Players | Amgen (REPATHA), Sanofi/Regeneron (PRALUENT), Merck (MK-0616), LIB Therapeutics (LIB003), AstraZeneca and Among Others |
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report?
please let us know !
please let us know !
PCSK9 Inhibitors Market Analysis
The PCSK9 inhibitors market is estimated to be valued at USD 2.44 Bn in 2024 and is expected to reach USD 6 Bn by 2031, growing at a compound annual growth rate (CAGR) of 16.2% from 2024 to 2031. The major factors driving the growth of this market are the increasing cases of hypercholesterolemia and cardiovascular diseases among the growing geriatric population.